Table 5.

Adverse effects

3 Months Prednisolone6 Months PrednisoloneP Value
BP≥P95
 At diagnosis36/61 (59%)28/62 (45%)0.15
 At 3 months FU12/57 (21%)7/60 (12%)0.21
 At 6 months FU8/55 (14%)10/52 (19%)0.61
Cushingoid appearance at 6 months FU
  Cushing (moon face)14/59 (23.7%)21/58 (36.2%)0.14
  Striae 3/58 (5.2%)4/60 (6.7%)1.00
Ophtalmological abnormalities at 6 months FU
 Glaucoma0/51 (0.0%)0/45 (0.0%)
 Cataract1/53(1.9%)a0/46 (0.0%)1.00
Severe infections
 Pneumonia1/62 (1.6%)6/64 (9.4%)0.16
 Meningitis0/62 (0.0%)0/64 (0.0%)
 Osteomyelitis0/62 (0.0%)0/64 (0.0%)
 VZV reactivation2/62 (3.2%)1/64 (1.6%)0.62
 Whooping cough0/62 (0.0%)2/64 (3.1%)0.50
 Miscellaneousb3/62 (4.8%)1/64 (1.6%)0.36
 Overall6/62 (9.7%)10/64 (15.6%)0.42
Dyspepsia1/62 (1.6%)2/64 (3.1%)1.00
Thrombosis0/62 (0.0%)0/64 (0.0%)
  • Data are expressed as number of events/number analyzed (percentages). FU, follow-up; VZV, Varicella Zoster virus.

  • a Mild cataract, which was absent at diagnosis.

  • b Three-month group: n=1 cellulitis, n=1 muscle abscess, n=1 intracranial abscess. Six-month group: n=1 appendicitis.